For thirty years, patients with locally advanced pancreatic cancer had no new treatment option: the tumor is too deeply embedded in neighboring blood vessels for surgery, but still without distant metastases. In February 2026, the FDA changed that. With approval of Optune Pax from Swiss company Novocure came the first device that fights cancer cells not chemically but physically, extending survival time in a clinical trial.
Thirty Years Without a New Standard
Pancreatic cancer kills approximately 19,500 people annually in Germany, making it one of the most common cancer-related causes of death, with a five-year survival rate below 13 percent. The main reason lies in anatomy. The pancreas sits deep in the abdomen, surrounded by other organs, and causes few symptoms early on. At diagnosis, roughly half of all patients already have distant metastases.
About one-third of patients are in locally advanced stage at initial diagnosis: the tumor has invaded neighboring blood vessels, surgery is impossible, but metastases in other organs do not yet exist. For exactly this group, gemcitabine chemotherapy has been standard since the late 1990s. This standard has not fundamentally changed in three decades.
What Electrical Fields Do to Cancer Cells
Optune Pax looks unspectacular: electrode arrays are attached to the torso and generate alternating electrical fields at roughly 150 kilohertz. These fields are too weak to heat tissue. But they are strong enough to interfere with cell division.
The mechanism is physical. When a cell divides, it builds a spindle apparatus from long protein filaments (microtubules) that distributes chromosomes to the two daughter cells. These structures have pronounced electrical polarization. The alternating field disrupts their orientation and forces the cell into faulty mitosis: cancer cells die without successfully dividing. Healthy cells divide rarely in most body regions and are barely affected by the field. This makes the procedure more selective than classical chemotherapy, which attacks all rapidly dividing cells.
Patients wear the device during ongoing chemotherapy. It is not tied to hospitalization; everyday activities, work and sleep remain possible according to study data.
What the PANOVA-3 Study Shows
The FDA approval is based on the Phase 3 PANOVA-3 study, which included 571 patients with locally advanced pancreatic carcinoma. One half received the established combination of gemcitabine and nab-paclitaxel, the other half the same chemotherapy plus Optune Pax.
Median overall survival rose from 14.2 to 16.2 months. The difference is statistically significant (Hazard Ratio 0.82; p=0.039). Even more striking is the one-year survival rate: 68.1 percent of patients in the Optune Pax arm survived the first treatment year, compared to 60.2 percent in the control group. In the group wearing the device at least 18 hours daily as recommended, median survival was 18.3 versus 15.1 months. Systemic side effects from chemotherapy were not worsened by Optune Pax; the most common device-specific complaints were mild skin irritations under the electrodes.
In Comparison: TTFields Proven Since 2011 in Glioblastoma
The physical principle is not new. Novocure first approved this technology in 2011 for glioblastoma, the most aggressive primary brain tumor. In the EF-14 Phase 3 study with 695 patients, Optune together with chemotherapy temozolomide improved median overall survival from 16.0 to 20.9 months (Hazard Ratio 0.63; p less than 0.001). The method is now anchored in international glioblastoma guidelines.
In pancreatic cancer, absolute survival numbers are smaller, but the comparison standard is different. When FOLFIRINOX received approval in 2011 for metastatic pancreatic cancer, it improved median survival from 6.8 to 11.1 months versus gemcitabine alone (PRODIGE 4/ACCORD 11, New England Journal of Medicine 2011). That was the largest therapeutic leap for metastatic disease so far. For the locally advanced setting, there had been no Phase 3 study with positive results since then.
21,000 Dollars Per Month: The Access Question
The approval is not without limitations. Optune Pax costs roughly 21,000 US dollars per month in the United States. For a typical treatment period of twelve to eighteen months, costs add up to an amount unreachable for most patients without full insurance coverage. In the U.S., reimbursement by Medicare and private insurers is not yet settled.
The Pancreatic Cancer Action Network (PanCAN), the largest U.S. patient organization for pancreatic cancer, welcomed the approval while emphasizing the need for broad reimbursement for all patients regardless of financial situation. Similar debates had occurred previously with Optune for glioblastoma, where some insurers initially refused coverage.
Three Hurdles Until European Public Insurance Coverage
For patients in Germany, at least three steps are necessary. First, Optune Pax needs CE marking under the European Medical Device Regulation (MDR); this does not yet exist for pancreatic cancer. Second, the device must be recognized as a New Examination and Treatment Method (NUB) for inpatient care. Third, the Joint Federal Committee (G-BA) decides on the method within statutory health insurance before funds regularly cover costs. Novocure has reportedly opened discussions with European authorities; a concrete timeline is not publicly known.
For glioblastoma, for which Novocure has completed the CE process, Optune is used in German inpatient treatment. This shows the procedure works in Europe. For pancreatic cancer patients, however, regular insurance coverage likely takes several more years.